Literature DB >> 11095854

HIV and Hepatitis Virus Infection.

.   

Abstract

As the life expectancy of patients with HIV infection increases, greater attention will need to be focused on concurrent illnesses, such as viral hepatitis, that may increase mid- to long-range morbidity and mortality. The incidence of viral hepatitis is increased in patients with HIV disease, reflecting the epidemiologic risks that these two conditions share. Coinfection with HIV seems to adversely affect the natural history of hepatitis C but may actually reduce the hepatic damage associated with hepatitis B. Immunosuppression due to HIV does not seem to significantly affect hepatitis A, E, or G. Clinicians have been reluctant to treat viral hepatitis in the HIV-infected population, but this therapeutic nihilism is unwarranted. Most studies have concluded that the treatment of hepatitis C in HIV-infected patients results in an initial efficacy and a long-term response similar to those seen in the HIV-seronegative population. Although the efficacy of interferon is reduced against hepatitis B, some nucleoside analogues are effective.

Entities:  

Year:  2000        PMID: 11095854     DOI: 10.1007/s11908-000-0031-y

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.663


  56 in total

1.  Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient.

Authors:  M Velasco; A Morán; M J Téllez
Journal:  N Engl J Med       Date:  1999-06-03       Impact factor: 91.245

2.  Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.

Authors:  Y Benhamou; C Katlama; F Lunel; A Coutellier; E Dohin; N Hamm; R Tubiana; S Herson; T Poynard; P Opolon
Journal:  Ann Intern Med       Date:  1996-11-01       Impact factor: 25.391

3.  The interaction of human immunodeficiency virus infection and hepatitis B virus infection in infected homosexual men.

Authors:  A L Mai; C Yim; K O'Rourke; E J Heathcote
Journal:  J Clin Gastroenterol       Date:  1996-06       Impact factor: 3.062

4.  Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. The Hepatitis/HIV Spanish Study Group.

Authors:  J García-Samaniego; V Soriano; J Castilla; R Bravo; A Moreno; J Carbó; A Iñiguez; J González; F Muñoz
Journal:  Am J Gastroenterol       Date:  1997-07       Impact factor: 10.864

5.  Response to hepatitis A vaccination in human immunodeficiency virus-infected and -uninfected homosexual men.

Authors:  G A Neilsen; N J Bodsworth; N Watts
Journal:  J Infect Dis       Date:  1997-10       Impact factor: 5.226

6.  Carriage of GB virus C/hepatitis G virus RNA is associated with a slower immunologic, virologic, and clinical progression of human immunodeficiency virus disease in coinfected persons.

Authors:  J J Lefrère; F Roudot-Thoraval; L Morand-Joubert; J C Petit; J Lerable; M Thauvin; M Mariotti
Journal:  J Infect Dis       Date:  1999-04       Impact factor: 5.226

7.  Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection.

Authors:  P Martin; A M Di Bisceglie; C Kassianides; M Lisker-Melman; J H Hoofnagle
Journal:  Gastroenterology       Date:  1989-12       Impact factor: 22.682

8.  Hepatitis C virus infection in the mothers and infants cohort study.

Authors:  M O Granovsky; H L Minkoff; B H Tess; D Waters; A Hatzakis; D E Devoid; S H Landesman; A Rubinstein; A M Di Bisceglie; J J Goedert
Journal:  Pediatrics       Date:  1998-08       Impact factor: 7.124

9.  [Effects of double and triple antiretroviral agents on the HCV viral load in patients coinfected with HIV and HCV].

Authors:  G Gavazzi; G Richallet; P Morand; O Bouchard; A Bosseray; P Leclercq; M Micoud
Journal:  Pathol Biol (Paris)       Date:  1998-06

10.  Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection.

Authors:  S C Hadler; F N Judson; P M O'Malley; N L Altman; K Penley; S Buchbinder; C A Schable; P J Coleman; D N Ostrow; D P Francis
Journal:  J Infect Dis       Date:  1991-03       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.